131 related articles for article (PubMed ID: 38331131)
1. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
3. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
4. Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab.
Benelli R; Costa D; Salvini L; Tardito S; Tosetti F; Villa F; Zocchi MR; Poggi A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543375
[TBL] [Abstract][Full Text] [Related]
5. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
6. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
8. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
Cui J; Zhang X; Huang G; Zhang Q; Dong J; Sun G; Meng Q; Li S
Mol Pharm; 2019 Jan; 16(1):409-421. PubMed ID: 30481041
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
11. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
12. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
13. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
14. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in
Parseghian CM; Sun R; Woods M; Napolitano S; Lee HM; Alshenaifi J; Willis J; Nunez S; Raghav KP; Morris VK; Shen JP; Eluri M; Sorokin A; Kanikarla P; Vilar E; Rehn M; Ang A; Troiani T; Kopetz S
J Clin Oncol; 2023 Jan; 41(3):460-471. PubMed ID: 36351210
[TBL] [Abstract][Full Text] [Related]
18. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
19. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
20. Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
Torlot L; Jarzab A; Albert J; Pók-Udvari Á; Stahler A; Holch JW; Gerlinger M; Heinemann V; Klauschen F; Kirchner T; Kumbrink J; Küster B; Jung A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):669-682. PubMed ID: 36401637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]